Aligos Therapeutics, Inc. Common Stock (ALGS) is a publicly traded Healthcare sector company. As of May 21, 2026, ALGS trades at $5.68 with a market cap of $33.17M and a P/E ratio of -0.63. ALGS moved +8.11% today. Year to date, ALGS is -33.41%; over the trailing twelve months it is -7.59%. Its 52-week range spans $3.76 to $46.80. Analyst consensus is strong buy with an average price target of $73.25. Rallies surfaces ALGS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aligos inks Greater China HBV drug deal with $25m upfront, $420m potential: Aligos Therapeutics granted exclusive Greater China rights to its HBV drug pevifoscorvir sodium under a licensing pact with Xiamen Amoytop, securing a $25m upfront payment. The deal offers up to $420m in milestones, tiered high-single-digit royalties and extends Aligos’ cash runway into late 2026.
| Metric | Value |
|---|---|
| Price | $5.68 |
| Market Cap | $33.17M |
| P/E Ratio | -0.63 |
| EPS | $-8.79 |
| Dividend Yield | 0.00% |
| 52-Week High | $46.80 |
| 52-Week Low | $3.76 |
| Volume | 1.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.71M |
| Net Income | $-90.32M |
| Gross Margin | 0.00% |
4 analysts cover ALGS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $73.25.